Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05441267
PHASE4

A Study of Cardiovascular Events iN Diabetes Plus

Sponsor: University of Oxford

View on ClinicalTrials.gov

Summary

ASCEND PLUS is testing whether, for people with type 2 diabetes who have not previously had a heart attack or stroke, regularly taking a tablet called semaglutide can safely help to reduce heart attacks, strokes, mini-strokes, the need for any procedures to unblock or bypass an artery to their heart, and the chance of dying because of vascular problems.

Key Details

Gender

All

Age Range

55 Years - Any

Study Type

INTERVENTIONAL

Enrollment

20000

Start Date

2023-03-13

Completion Date

2048-08-17

Last Updated

2024-05-08

Healthy Volunteers

No

Interventions

DRUG

Semaglutide Oral Tablet

Oral semaglutide 14mg daily (option to reduce to 7mg daily)

DRUG

Placebo oral tablet

Placebo oral semaglutide

Locations (1)

Clinical Trial Service Unit and Epidemiological Studies Unit

Oxford, United Kingdom